Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frontline Lenalidomide for AL Amyloidosis Involving Myocardium
NCT04298372Phase 3Completed
- Sponsor
- Seoul National University Hospital
- Start
- Feb 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lenalidomide in immunoglobulin light chain amyloidosis, sponsored by Seoul National University Hospital. Started Feb 2019; status: completed.
02
Drugs
lenalidomide
03
Conditions
immunoglobulin light chain amyloidosis
Beyond the preview
Go deeper on NCT04298372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04298372.